Jörres, Rudolf A.
Buess, Christian
Piecyk, Andreas
Thompson, Bruce
Stanojevic, Sanja
Magnussen, Helgo
Funding for this research was provided by:
ndd Medical Technologies, Technopark Zurich, Zurich, Switzerland
Article History
Received: 19 May 2023
Accepted: 26 February 2024
First Online: 13 March 2024
Declarations
:
: The study protocol (clinicaltrial.gov NCT04531293, first trial registration 28/08/2020) was approved by the local ethics committee (Kantonale Ethikkommission Zürich (Cantonal Ethics Committee Zurich), BASEC 2020–02139), and all participants gave their written informed consent. All experiments were performed in accordance with relevant guidelines and regulations, in particular the Declaration of Helsinki.
: Not applicable.
: Research support: Christian Buess, employee of ndd reports financial support, administrative support, article publishing charges, and equipment, drugs, or supplies were provided by ndd SwitzerlandRelationships: Christian Buess reports a relationship with ndd Switzerland that includes: employment.Patents and Intellectual Property: There are not patents to disclose.Other Activities: Helgo Magnussen received compensation for medical advice until 2022. Bruce Thompson and Sanja Stanojevic are members of the Advisory Board of ndd that has been created in 2023. Rudolf A. Jörres and Andreas Piecyk have nothing to disclose.